Lung cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• EGFR 301
• PD-L1 161
• PD-1 157
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• mTOR 0
• VEGF 23
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 12
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• HDAC 0
• EZH2 2
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

EU-13 is a filter, not a ranking: it only narrows the list.

8 of 8+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

  NCT06287463· Deciphera Pharmaceuticals, LLC· Updated 5 Mar 2026

  “Trial terminated due to a business decision, not based on any safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

  NCT05578092· Mirati Therapeutics Inc.· Updated 19 Feb 2026

  “business objectives have changed”Registry text, quoted unchanged. Source

• Terminated

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Ikena Oncology· Updated 19 Sept 2025

  “Limited resources and strategic priorities”Registry text, quoted unchanged. Source

• Suspended

  JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

  NCT04418167· JS InnoPharm, LLC· Updated 3 Sept 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

  NCT07121829· Day One Biopharmaceuticals, Inc.· Updated 14 Aug 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

  NCT05375084· Navire Pharma Inc., a BridgeBio company· Updated 12 Dec 2024

  “Business reasons”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 313
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 66
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 190
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 616
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 115
• Machine Learning 290
• Deep Learning 210
• Cohort Studies 289
• Genome-Wide Association Study 75

• Machine learning prognostic model and drug survival analysis for lung adenocarcinoma in the context of radiotherapy.

  Pak J Pharm Sci, Dec 2026

• Development and validation of a machine learning model and nomogram for predicting lung metastasis in thymoma: A population-based study.

  Medicine (Baltimore), Nov 2026

• Integrating Machine Learning to Identify Prognostic Subtypes and the Cisplatin Resistance Gene RRM2 in Lung Adenocarcinoma.

  Thorac Cancer, Nov 2026

• Machine learning-assisted Ti3C2Tx MXene/Au@Fe3O4 core-shell nanocomposite-based electrochemical genosensor for ultrasensitive detection of EGFR T790M mutation in lung cancer.

  Mikrochim Acta, Oct 2026

• Differential Diagnosis of Early-Stage Pulmonary Sarcoidosis With Normal Serum Angiotensin-Converting Enzyme Activity Using Peripheral Blood Indicators: Machine Learning Models Development and Validation.

  JMIR Med Inform, Oct 2026

• Machine learning-derived intracellular protein-based prognostic model reflecting a senescence-associated secretory phenotype-driven immunosuppressive microenvironment in lung adenocarcinoma.

  PeerJ, Oct 2026

• Predicting lymph node metastasis in non-small cell lung cancer using clinical and PET/CT-derived morphological features: An interpretable machine-learning study.

  PLoS One, Oct 2026

• Machine Learning, Radiomics, and Clinical Models Predicting Checkpoint Inhibitor Pneumonitis in Lung Cancer: A Systematic Review and Meta-analysis.

  J Vis Exp, Oct 2026

• Predicting miRNA-Disease Associations Based on Contrastive Learning of Linear and Nonlinear Features.

  Genes (Basel), Oct 2026

• Integrated multi-omics, network pharmacology, and machine learning reveal the active constituents and pharmacological mechanism of Fufang E'jiao Jiang against lung cancer-related fatigue.

  Anal Chim Acta, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.